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Abstract
Background Congenital nephrotic syndrome (CNS) of the
Finnish type, NPHS1, is the most severe form of CNS.
Outcomes of renal replacement therapy (RRT) in NPHS1 pa-
tients in Europe were analysed using data from the ESPN/ERA-
EDTARegistry. As NPHS1 is most prevalent in Finland and the
therapeutic approach differs from that in many other countries,
we compared outcomes in Finnish and other European patients.
Methods NPHS1 mutations were confirmed in 170 children
with CNSwho initiated RRT (dialysis or renal transplantation)
between 1991 and 2012. Finnish (n = 66) and non-Finnish
NPHS1 patients (n = 104) were compared with respect to
treatment policy, age at first RRT and renal transplantation
(RTX), patient and graft survival, estimated glomerular filtra-
tion rate (eGFR) and growth. Age-matched patients with con-
genital anomalies of the kidney and urinary tract (CAKUT)
served as controls.
Results Finnish NPHS1 patients were significantly youn-
ger than non-Finnish patients, both at the start of RRT
and at the time of RTX. We found similar overall 5-
year patient survival on RRT (91 %) and graft survival
(89 %) in both NPHS1 groups and CAKUT controls. At
the start of RRT, height standard deviation score (SDS)
was higher in Finnish patients than in non-Finnish pa-
tients (mean [95 % CI]: −1.31 [−2.13 to −0.49] and
−3.0 [−4.22 to −1.91], p < 0.01 respectively), but not
at 5 years of age. At 5 years of age height and body
mass index (BMI) SDS were similar to those of
CAKUT controls.
Conclusions Overall, 5-year patient and graft survival of
both Finnish and non-Finnish NPHS1 patients on RRT
were excellent and comparable with CAKUT patients
with equally early RRT onset and was independent of
the timing of RRT initiation and RTX.
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Introduction
Congenital nephrotic syndrome (CNS) is a rare kidney disease
defined by heavy proteinuria starting within 3 months after
birth. Most cases of CNS are caused by genetic defects in
different components of the glomerular filtration barrier, espe-
cially mutations in NPHS1 (nephrin) and NPHS2 (podocin),
WT1, LamB2 and PLCE1 genes [1–4]. NPHS1 usually leads
to a severe form of CNS, the so-called Finnish type (NPHS1),
which is highly prevalent in Finland [3]. Worldwide, over 200
mutations have been identified in the NPHS1 gene
(http://www.ncbi.nlm.nih.gov/gene/4868) and most patients
have individual mutations. However, in Finland two equally
severe truncating nonsense mutations (Fin-major and Fin-
minor) are present in over 90 % of the patients [3].
There is relatively limited phenotypic variation in
NPHS1 in Finnish patients [5]. Most children are born pre-
maturely after an uneventful pregnancy. The placental
weight is more than 25 % of the weight of the newborn in
almost all cases [5, 6]. Severe proteinuria begins mostly in
utero and, without therapy, results in oliguria and severe
oedema soon after birth. NPHS1 infants do not have
extra-renal malformations, but muscular hypotonia and car-
diac hypertrophy are common during the nephrotic stage.
Most Bnon-Finnish^ mutations in NPHS1 lead to a
severe phenotype, with an early onset of nephrotic syn-
drome, similar to Finnish patients [7]. However, cases
involving a milder course of disease and/or later onset
(up to adulthood) of nephrotic syndrome have also been
described [8–10]. The presence of at least one non-trun-
cating, Bmild^ mutation explains the phenotype of these
patients.
Patients with severe NPHS1 do not respond to captopril
and indomethacin therapy for controlling proteinuria [3, 11].
In Finnish NPHS1 patients, timely bilateral nephrectomy and
commencement of peritoneal dialysis (PD; when weight is
approximately 7 kg) followed by renal transplantation
(RTX) has been the therapeutic approach of choice for many
years [3, 6]. In an attempt to delay dialysis and its inherent
complications, Coulthard proposed an alternative strategy,
with unilateral nephrectomy, which would lead to reduced
protein losses and easier management of the patient [12, 13].
This management principle has been adopted in many centres
during the past decade [11, 14]. Another approach has been to
perform early pre-emptive RTX and remove the nephrotic
kidneys. However, this strategy has been shown to predispose
to thrombotic complications of the graft [15]. As detailed data
on outcomes in this population are scarce, the optimal treat-
ment strategy for this complex disease is unclear. Therefore,
the objective of this study was to describe renal replacement
therapy (RRT) outcomes of Finnish and non-Finnish NPHS1
patients who survived the nephrotic phase and initiated RRT,
and to compare their outcomes with those of age-matched
RRT patients with congenital anomalies of the kidney and
urinary tract (CAKUT) registered in the ESPN/ERA-EDTA
Registry.
Subjects and methods
Data collection
We included data on children with NPHS1 whose muta-
tion was confirmed by their treating physician and who
started RRT (dialysis or renal transplantation) between 1
January 1991 and 31 December 2012 collected within the
framework of the European Society for Paediatric
Nephrology/European Renal Associat ion and the
European Dia lys i s and Transp lan t Assoc i a t i on
(ESPN/ERA-EDTA) Registry. Details on neither the mu-
tation nor the type of sequencing have been reported to
the Registry. On an annual basis, the Registry collects
individual patient data on date of birth, sex, treatment
and date of first RRT, and on subsequent changes in treat-
ment modalities for all European children with end-stage
renal disease (ESRD) [16]. Furthermore, for most coun-
tries, anthropometric and biochemical data are available
(77 % of the NPHS1 patients). We identified patients from
the following countries: Austria, Belgium, Finland,
France, Italy, the Netherlands, Norway, Russia, Spain,
Sweden, Switzerland, Slovakia, Turkey and the UK. No
NPHS1 patients were identified in the following coun-
tries: Czech Republic, Estonia, Lithuania and Slovenia.
Causes of death were grouped according to the ERA-
EDTA coding system: cardiac failure and cardiac arrest/
sudden death; other cause or unknown were combined as
Bcardiovascular mortality^ [17].
Patients were divided into two groups: the NPHS1 patients
from Finland and the NPHS1 patients from other countries. A
group of CAKUT patients age-matched to the non-Finnish
NPHS1 patients served as controls. Three control patients
were selected for each NPHS1 patient.
Definition of variables
Height values were normalized to standard deviation
scores (SDS) for chronological age, according to recent
national growth charts or growth charts for Northern or
Southern European countries [18]. Body mass index
(BMI) was calculated as weight/height2 and expressed
according to chronological age (0–1 years) or height–
age (≥2 years) [19]. Reference charts from the World
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Health Organization were used to calculate SDS values
for BMI [20, 21]. Estimated glomerular filtration rate
(eGFR) was calculated according to the bedside
Schwartz formula [22].
Statistical analyses
Baseline demographic and clinical characteristics were
calculated as medians and interquartile ranges (IQRs;
continuous variables) or proportions (categorical vari-
ables). To compare the groups, we used the Kruskal–
Wallis test for continuous variables and the Chi-
squared test for categorical variables. Patient survival
was calculated from the time of initiation of RRT until
death, loss to follow-up or the end of observation (31
December 2012), whichever came first. Graft survival
was analysed both including and excluding death with
functioning graft as a cause of graft failure. The
Kaplan–Meier method was used for calculation of unad-
justed patient and graft survival (including death),
whereas a competing risk method was applied to esti-
mate unadjusted death-censored graft survival and pa-
tient survival after transplantation [23]. Risk factors for
mortality were analysed using Cox proportional hazard
regression models, adjusted for potential confounders.
Linear mixed models with both a random intercept and
a random slope for chronological age were used to
model the evolution of height and BMI SDS. An un-
structured correlation matrix structure was assumed.
Adjustments were made for treatment modality.
Statistical tests were two-tailed and were consid-
ered significant when p < 0.05. Data were analysed
using SPSS version 20 (SPSS, Chicago, IL, USA)
and SAS version 9.3 (SAS Institute, Cary, NC,
USA).
Results
Patient characteristics
A total of 170 patients with CNS caused by NPHS1
mutation were extracted from the ESPN/ERA-EDTA
Registry. Sixty-six patients were from Finland and 104
from other countries. Median age at start of RRT was
significantly lower in the Finnish (0.7 [IQR: 0.6–0.8]
years) compared with non-Finnish NPHS1 patients (1.7
[IQR: 1.0–2.9] years; p < 0.01; Fig. 1, Table 1). Of the
non-Finnish patients, 9.9 % received a pre-emptive
RTX, 68.3 % initiated RRT while on PD and 21.8 %
while on haemodialysis (HD). All Finnish patients initi-
ated RRT while on PD and none underwent pre-emptive
RTX (Table 1).
Patient survival
Sixteen NPHS1 patients (6 Finnish [5 on dialysis] and 10 non-
Finnish [7 on dialysis]) out of 170 died while on RRT at a
median age of 1.4 (IQR: 1.0–2.0) and 2.9 (IQR: 1.1–5.0) years
respectively, whereas 33 (22 on dialysis) out of 312 patients
from the CAKUT control group died at a median age of 2.3
(IQR: 1.3–6.0) years. The cause of death was known for 63 %
of patients (83.3 % Finnish NPHS1, 60 % non-Finnish
NPHS1, 61 % CAKUT). Infection was the most common
known cause of death in all groups and accounted for 50 %,
20 % and 21 % of the fatalities in Finnish NPHS1, non-
Finnish NPHS1 and CAKUT patients, respectively.
The overall unadjusted 5-year patient survival on RRTwas
91 % in both Finnish and non-Finnish NPHS1 and 90 % in
CAKUT patients (p = 0.83; Fig. 2a). There was no difference
among the groups with regard to unadjusted patient survival
according to chronological age. After adjustment for age at the
start of RRT and sex, the risks of death of Finnish (adjusted
hazard ration [aHR]: 0.53, 95 % CI: 0.21–1.33) and non-
Finnish NPHS1 patients (aHR: 0.84, 95 % CI: 0.40–1.80)
were similar to that of CAKUT patients.
Five-year patient survival after first RTX was also similar
in all three groups of patients: 98.4 % in Finnish NPHS1,
97.8 % in non-Finnish NPHS1, and 96.6 % among control
patients (p = 0.42). The risk of death post-RTX remained sim-
ilar to CAKUT controls after adjustment for age at RTX and
sex (aHR: 0.32, 95 % CI: 0.04–2.86 for Finnish NPHS1 and
aHR: 0.45, 95 % CI: 0.09–2.35 for non-Finnish NPHS1).
When comparing NPHS1 patients, Finnish patients had a
similar risk of death as the non-Finnish ones after adjustment
for age at RRT and sex (aHR: 0.79, 95 % CI: 0.25–2.48).
NPHS1 patients who started RRT at below 1 year of age
(aHR: 1.36, 95 % CI: 0.31–5.96) and patients who were aged
1 to 2.5 years (aHR: 0.54, 0.95 % CI: 0.11–2.70) had a similar
risk of death as NPHS1 patients who were over 2.5 years of
Fig. 1 Age at start of renal replacement therapy (RRT) for Finnish and
non-Finnish NPHS1 patients and for age-matched congenital anomalies
of kidney and urinary tract controls for the non-Finnish NPHS1 patients
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age when commencing RRT. Among transplanted patients,
time to RTX was not associated with patient survival; aHR
for each additional year was 0.04 (95 % CI: 0.00–1.47).
Renal transplantation and graft survival
The majority of patients (88.8 %) received a renal transplant
during the observation period after a median dialysis time of
0.9 years (Table 2). The median interval between initiation of
RRT and undergoing a transplant did not differ between
Finnish (0.9 [IQR: 0.6–1.4] years) and non-Finnish NPHS1
patients (1.0 [IQR: 0.3–1.7] years; p = 0.69; Table 2). The
median age at RTX was 1.6 (IQR: 1.2–2.1) years in Finnish
and 3.0 (IQR: 1.7–4.4) years in non-Finnish patients respec-
tively (p < 0.01).
The proportion of living donor RTX was similar in both
groups (30 % vs 35 % in Finnish and non-Finnish NPHS1
patients respectively, p = 0.52).
The graft survival of the first RTX is shown in Fig. 2b.
After a median follow-up of 8.5 years, 26 grafts (including 3
deaths) were lost, 11 (18 %) in Finnish and 15 (17 %) in non-
Finnish NPHS1 patients. Graft survival did not differ between
these two groups and was 89% after 5 years of follow-up. The
5-year graft survival was comparable in the 10 subjects
transplanted pre-emptively (80 %). Results were similar when
considering death as a competing event (data not shown).
Despite equal graft survival, median eGFR was significantly
lower in Finnish NPHS1 patients than in non-Finnish NPHS1
patients at 5 years after RTX (Table 2). It should, however, be
noticed that 5-year eGFR was available only for 24 % of non-
Finnish and 64 % of Finnish NPHS1 patients.
Graft survival of NPHS1 patients did not differ com-
pared with age-matched CAKUT patients (Fig. 2b) and
remained similar after adjustment for age at RTX and
sex (aHR Finnish NPHS1: 0.83, 95 % CI: 0.40–1.70;
aHR non-Finnish NPHS1: 0.96, 95 % CI: 0.51–1.80).
Growth and BMI
Modelled patterns of height and BMI SDS are shown in
Fig. 3. Height SDS at the start of RRT was higher in
Finnish NPHS1 (−1.31; 95 % CI: −2.13 to −0.49) com-
pared with non-Finnish NPHS1 (−3.0; 95 % CI: −4.22 to
−1.81) or CAKUT patients (−2.22; 95 % CI: −2.83 to
−1.61), and at the time of RTX. It should, however, be
noted that Finnish NPHS1 patients were much younger
when commencing RRT and when receiving their first
renal graft. At the age of 5 years, there were no signifi-
cant differences in height SDS between the groups. Data
Table 1 Characteristics of
NPHS1 patients and congenital
anomalies of kidney and urinary
tract (CAKUT) controls at the
time of RRT initiation. Values are
given as median (IQR) or number
(%)
Variable Overall NPHS1
(n = 170)
Finnish NPHS1
(n = 66)
Non-Finnish NPHS1
(n = 104)
CAKUT controls
(n = 312)
Age 0.9 (0.6-1.9) 0.7 (0.6-0.8) 1.7 (1.0-2.9) 1.7 (0.9-2.8)
Females 91 (53.3) 31 (47.0) 60 (57.7) 61 (19.6)
Initial RRT modalitya
PD 135 (80.8) 66 (100) 69 (68.3) 188 (60.3)
HD 22 (13.2) 0 22 (21.8) 38 (12.2)
RTX 10 (6.0) 0 10 (9.9) 66 (21.2)
RRT renal replacement therapy, PD peritoneal dialysis, HD haemodialysis, RTX renal transplantation
aMissing for three non-Finnish patients and 20 CAKUT controls
Fig. 2 a Patient survival since start of renal replacement therapy (RRT)
and b 5-year graft survival (including death) for Finnish and non-Finnish
NPHS1 patients and for age-matched congenital anomalies of kidney and
urinary tract controls for the non-Finnish NPHS1 patients
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on growth hormone (rhGH) use was available in all
Finnish NPHS1 patients, in 55 non-Finnish NPHS1 pa-
tients (52.8 %) and in 55.4 % of CAKUT controls. The
overall ever use of rhGH was lower in Finnish NPHS1
patients (10.6 %) compared with non-Finnish NPHS1
(30.9 %) and CAKUT patients (27.2 %).
Standard deviation scores for BMI showed different pat-
terns between the start of RRT and the age of 5 years for the
three groups of patients. At the start of RRT, mean BMI SDS
was lowest among Finnish NPHS1 (0.30; 95 % CI: −0.39 to
0.98), followed by CAKUT patients (0.49; 95 % CI: −0.09 to
1.07) and non-Finnish NPHS1 patients (1.68; 95%CI: 0.54 to
Table 2 Transplantation
characteristics by patient sub-
groups. Values are given as
median (IQR) or number (%)
Variable Overall (n = 170) Finnish
NPHS1 (n = 66)
non-Finnish
NPHS1 (n = 104)
P value
Patients receiving transplant 151 (88.8) 61 (92.4) 90 (86.5) 0.24
Age at RTX (years) 2.1 (1.4–3.5) 1.6 (1.2–2.1) 3.0 (1.7–4.4) <0.01
Dialysis time (years) 0.9 (0.6–1.7) 0.9 (0.6–1.4) 1.0 (0.3–1.7) 0.69
Patients with LRD RTX 47 (32.4)
(n = 145)
18 (29.5)
(n = 61)
29 (34.5)
(n = 84)
0.52
eGFR at 1 year
(ml/min/1.73 m2)
58 (51–85)
(n = 76)
57 (47–77)
(n = 52)
71 (55–95)
(n = 24)
0.08
eGFR at 5 years
(ml/min/1.73 m2)
61 (47–77)
(n = 67)
54 (47–67)
(n = 42)
69 (59–83)
(n = 25)
<0.01
RTX renal transplantation, eGFR estimated glomerular filtration rate, LRD living related donor
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Height SDS BMI SDSFig. 3 Modelled evolution of
height standard deviations score
(SDS) and body mass index
(BMI) SDS by chronological age
in Finnish and non-Finnish
NPHS1 patients compared with
age-matched congenital
anomalies of kidney and urinary
tract controls. Adjustments were
made for treatment modality. Data
shown represent mean estimates
at the time of entering renal
replacement therapy (RRT), at the
time of renal transplantation
(RTX) and at the age of 5 years.
Two-dimensional error bars
indicate the mean age and SDS
and their respective 95 %
confidence intervals at the
different time points
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2.81). BMI SDS was significantly lower in Finnish than in
non-Finnish NPHS1 patients (p < 0.05). Between the start of
RRT and RTX, on average, BMI SDS increased slightly in
Finnish NPHS1 and CAKUT patients, whereas it decreased
in non-Finnish NPHS1 patients. However, at the age of
5 years, there were no significant differences in the mean
BMI SDS among the three groups (Fig. 3).
Discussion
To our knowledge, this ESPN/ERA-EDTA Registry study on
170 children with NPHS1 is the largest outcome study on this
very rare disease performed to date. Given the severe early
course of the disease, we found good 5-year patient and graft
survival periods in patients who entered an RRT program,
which were comparable to age-matched RRT controls with
CAKUT. Notably, we did not find any significant differences
in outcomes between non-Finnish NPHS1 patients treated
with variable protocols and Finnish NPHS1 patients treated
with a uniform protocol involving early elective bilateral ne-
phrectomy to minimize infectious and thrombotic complica-
tions and to send patients to home care. It should, however, be
noted that Finnish NPHS1 patients may have had a more
serious form of the disease, because of severe mutations in
over 90 % of patients [3].
The literature on both CNS and NPHS1 is scarce. A single
large-scale registry study compared transplant outcomes in
132 CNS patients with those of other patients [15], whereas
other studies reported pooled outcomes of infants, including
only a few CNS/NPHS1 patients commencing dialysis or
RTX [24–28].
In general, children with ESRD up to 3–4 years of age have
the highest mortality rates during dialysis [29–32] and after
RTX [33], and the poorest graft survival [33]. However, we
observed very good patient and graft survival after starting
RRT in this challenging subgroup of NPHS1 infants, and no
differences were found between patients from Finland and
those from elsewhere in Europe. Patient and graft survival
periods were also similar to those of CAKUT controls age-
matched to the non-Finnish NPHS1 patients.
The 91 % 5-year patient survival in the present study was
similar to the 4-year patient survival of 87 % observed across
all ESRD patients aged 0–4 years in Europe in 2007–2011
[29]. Lower 5-year patient survival (75 %) has been reported
in a study from the same time period of 87 infants entering
RRT for different diseases in Canada, 57 of whom received
RTX at a median age of 2.7 years [25]. Mortality was highest
in the youngest patients [25]. In contrast to previous studies,
we found equal patient survival in both NPHS1 groups and
CAKUT controls, although the Finnish NPHS1 patients were
significantly younger at the start of RRT and at RTX. The
equal patient survival of Finnish and non-Finnish NPHS1,
despite the age difference, may be explained by the fact that
physicians have more experience in caring for infants on di-
alysis and RTX in Finland because the severe NPHS1 muta-
tion is more prevalent in the Finnish population.
The 5-year graft survival of 89 % in the present study was
slightly better than the survival observed in North American
transplanted infants and toddlers reported to the USRDS da-
tabase between 1995 and 2005 (70–81 % for deceased donor
transplants and 88–92 % for living donor transplants) [34].
The graft failure rate was significantly higher in 132 CNS
patients compared with other NAPRTCS Registry patients
who underwent transplantation between 1987 and 1997
(33 % compared with 24 %) [15], which was explained by a
higher rate of vascular thrombosis. Further, a recipient age of
less than 2 years in CNS patients, according to the NAPRTCS
report in the 1990s, was found to be a significant predictor for
poor graft survival [15]. Approximately half of the CNS pa-
tients in this study were nephrectomised, and no difference in
occurrence of thrombotic complications was found between
those who had been nephrectomised and those who had not. A
Finnish study from the early 1990s was more in concordance
with our study. Laine et al. did not find a difference in graft
survival by renal diagnosis in 39 young Finnish RTX patients
(59 %NPHS1), nor did the authors report thrombotic vascular
complications in NPHS1 patients [35]. The lack of thrombotic
vascular complications, contrary to the NAPRTCS report of
the 1990s, was explained by normalisation of the coagulation
system after bilateral nephrectomy, which was performed at
least 3 months before RTX. The difference in the occurrence
of thrombotic vascular complications in nephrectomised chil-
dren between these two studies may be associated with the
timing of the nephrectomy, possibly also with use of
anticoagulation. Kim et al. reported neither the timing of ne-
phrectomy, nor the use of anticoagulation, whereas the latter
has been part of the routine since the 1990s in the treatment of
NPHS1 patients in Finland before nephrectomy [15, 36].
Recent studies have shown a significant improvement in the
outcome of kidney transplantations in young children, which
has been mainly attributed to better neonatal care, withdrawal
of dialysis treatment from infants with very serious comorbid-
ities [24] and a reduction of acute rejections owing to im-
provements in organ allocation policy, perioperative care and
immunosuppressive medications [37]. Accordingly, excellent
graft survival (75 % at 10 years) without any impact of age at
RTX, has been reported in a single-centre study of 71 ESRD
infants undergoing transplantation at a median age of 3.2 years
[24].
Finnish NPHS1 patients were taller at the start of RRT and
at the time of RTX compared with non-Finnish NPHS1 and
CAKUT patients. However, this difference in height SDS dis-
appeared at the age of 5 years. The Finnish NPHS1 patients
differed from the others in respect of commencing dialysis at a
much younger age and without uraemia, which may have had
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an impact on height SDS at the start of RRT in the other
groups. Although not reported for every patient, rhGH was
used less frequently in Finnish compared with non-Finnish
NPHS1 patients and CAKUT controls, which together with
a lower BMI SDS, may partly explain the lack of catch-up
growth during RRT course in the Finnish NPHS1 patients.
The different evolution of BMI SDS in the Finnish and non-
Finnish patient groups may reflect differences in nutritional
management between countries [19]. Finnish children in-
creased their BMI SDS while on dialysis, but not following
RTX. This finding may reflect a particularly efficient enforce-
ment of nutritional targets in dialysed infants. The non-
Finnish NPHS1 patients underwent dialysis at ages when
growth is less affected by nutrition, which could explain their
catch-up growth, despite decreasing BMI SDS. In an
International Pediatric Dialysis Network (IPPN) Registry re-
port with 153 infants undergoing chronic PD in 2007–2009,
the median age (0.9 years) and height SDS (−2.4) at study
entry were comparable to our study [38]. The subgroup of
European children (n = 67) significantly improved their BMI
SDS while on dialysis; however, in contrast to NPHS1 pa-
tients from the present study, their BMI SDS stayed below
zero. Mekahli et al. reported better growth in a single-centre
study of 71 infants commencing dialysis and receiving RTX
during the same time period as our patients [24]. The authors
concluded that normal growth is possible in infants on dialysis
and after RTX, but it is labour-intensive and heavily depen-
dent on adequate renal dietician support. Compared with our
study, a high percentage of infants also received pre-emptive
RTX (44 %), which may have favoured catch-up growth [24].
The major strength of our study is the large number
of NPHS1 patients followed, which is to our knowledge
the largest cohort of this monogenic disease entity to
date. Furthermore, we compared the outcome of non-
Finnish NPHS1 patients with age-matched CAKUT pa-
tients. Contrary to the Finnish NPHS1 patients, non-
Finnish ones seemed to enter RRT when they reach
uraemia, but eGFR at the start of RRT was only avail-
able for a limited number of patients.
Some further limitations of our study need to be ac-
knowledged. Results of the present study only apply to
NPHS1 patients who survived the nephrotic period and
entered into an RRT programme. The ESPN/ERA-EDTA
Registry collects data from the start of RRT only, and,
unfortunately, no information is available on pre-RRT
treatment, the number of nephrectomies, or the number
of patients dying before RRT. However, the Finnish
patients commenced RRT within the first year of life,
and in the non-Finnish NPHS1 and CAKUT controls
there was a relatively short interval between birth and
RRT. Furthermore, as no differences in outcomes were
found, it is unlikely that pre-RRT management had had
a large impact on the outcomes in our study population.
As the ESPN/ERA-EDTA Registry includes only limited
information on nutritional therapy, growth hormone use,
albumin infusions and comorbidities (such as preterm
birth), we were not able to study the factors affecting
growth and BMI in more detail.
Management of NPHS1 patients is challenging, as
there are only very few patients over a long time span
in the majority of the centres, treatment protocols are
variable, and hardly any data exist on outcomes. This
study showed for the first time that it is worth treating
these challenging patients: NPHS1 patients’ outcomes
are similar to those of CAKUT infants and toddlers
who require RRT early in life. Both starting RRT early
with elective bilateral nephrectomy while eGFR is still
normal, and starting RRT later, after deterioration of the
kidney function, are safe management options with re-
gard to patient and graft survival and long-term growth
outcomes.
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